Sales Reps Prove Compelling Plaintiffs As Novartis Loses Jury Trial Gamble In Gender Discrimination Case; Pay Policy Could Change Industry-wide
Executive Summary
The jury verdict in the Novartis gender discrimination class action set a precedent that could impact the entire industry. It is the largest verdict ever awarded in such a case - and damages could extend well beyond that $253.4 million awarded so far if other members of the class come forward
You may also be interested in...
Gender Discrimination Suits: Cases Against Pharma Continue Even As Payouts Slow
Novartis will pay $8m to settle second case; last year Daiichi Sankyo settled gender discrimination class action for the same amount and action against Bayer was dismissed following confidential resolution. Cases are ongoing against Merck and Forest.
Novartis Will Track Gender Disparities In Performance Evaluations Under Settlement
Gender discrimination suit is resolved with Novartis paying $175 million, 45 percent less than a jury awarded plaintiffs.
Successful Novartis Sales Reps' Performance Scores Could Be Downgraded To Satisfy Budget Goals, Gender Discrimination Trial Reveals
Former head of human resources testifies at gender discrimination trial that 12 percent of a given employee population had to receive low performance ratings.